



NEWS RELEASE

Revvity Announces Development of High-Throughput T-SPOT.TB Automated Platform for Clinical Labs

2026-07-23

- New T-SPOT A201 platform engineered to deliver high-volume latent tuberculosis IGRA testing to meet the needs of high-throughput laboratories
- Intends to provide labs with a more highly automated workflow designed to support the performance characteristics associated with the T-SPOT.TB assay
- Built on the success of the Auto-Pure 2400 liquid handler, the platform is engineered as an accessible, scalable and efficient solution

WALTHAM, Mass. – July 23, 2026 – **Revvity, Inc.** today announced the development of the T-SPOT™ A201, a next-generation high-throughput automated platform designed to support the performance advantages of **T-SPOT.TB™** testing for large-volume clinical labs, enabling a reliable, accurate solution for latent tuberculosis (TB) detection.

Tuberculosis remains a critical global health challenge, with testing demand driven by immigration screening, pre-treatment evaluation for immunosuppressive therapies, and broader public health programs. It is crucial for labs to deliver accurate results upon initial testing, while managing a high volume of samples to support timely treatment and improved patient outcomes.

Building on the success of **the Auto-Pure 2400 liquid handler**, the T-SPOT A201 platform is engineered to meet the throughput requirements of large-scale testing environments, strengthening the Company's automation portfolio and its ability to support labs across a range of throughput needs. It can process up to 384 samples per instrument in an 8-hour shift, with 45 seconds per sample of hands-on time – the lowest of any T-SPOT automation solution. The platform aims to ensure that these labs benefit from the scalability and workflow advantages associated with

automated T-SPOT.TB testing.

"The T-SPOT A201 automation platform represents a significant step forward in making the benefits of T-SPOT.TB testing accessible at scale," said Steven Hart, vice president and general manager of infectious disease diagnostics at Revvity. "Our development program is focused on delivering a solution that gives high-volume clinical labs the performance, workflow efficiency, and competitive economics they need."

Additional studies on the performance of the Company's automation solutions will be released in the coming months. The T-SPOT A201 platform is currently under development and targeted for launch in the second half of 2027, subject to regulatory approval.

Revvity's Euroimmun business will be showcasing its latest automation solutions at the ADLM 2026 conference in Anaheim, California from July 26 – 30 at booth #1411, with a T-SPOT.TB breakfast workshop on July 28. To register, please visit the website [here](#).

The T-SPOT A201 platform is currently under development and not yet available for sale.

About Revvity

At Revvity, "impossible" is inspiration, and "can't be done" is a call to action. Revvity provides health science solutions, technologies, expertise, and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what's possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more.

With 2025 revenue of \$2.9 billion and approximately 11,000 employees, Revvity serves customers across pharmaceutical and biotech, diagnostic labs, academia and governments. It is part of the S&P 500 index and has customers in more than 160 countries.

Stay updated by following our [Newsroom](#), [LinkedIn](#), [X](#), [YouTube](#), [Facebook](#) and [Instagram](#).

Media Relations:

Chet Murray

(781) 462-5126

chet.murray@revvity.com